Mapping the evolution of E. coli’s main virulence factor offers a refined drug target

This new work focused on a particular subset of E. coli with a specific capsule - the extracellular barrier that surrounds a bacterium - which scientists have called K1. E. coli with this type of capsule are known to cause invasive diseases such as bloodstream or kidney infections, and meningitis in newborns.  This is because this particular cover allows them to mimic molecules already present in human tissues and enter the body unnoticed. 

The researchers present evidence that targeting the capsule can be used as the basis of treatment, paving the way to prevent serious E. coli infections. 

E. coli is a common cause of urinary tract and bloodstream infections and can cause meningitis in premature and term newborns, with a mortality rate as high as 40 per cent (2). Furthermore, the rise in hypervirulent and multi-drug resistant E. coli during the last decade means that developing effective strategies to prevent and treat E. coli has now become urgent. Understanding the bacterium’s anatomy and how this plays a role in causing disease is key for the prevention of serious infections. Scientists until now lacked basic knowledge of the prevalence, evolution and functional properties of the K1 capsule, limiting their capacity to combat E. coli infections. 

Researchers at the Wellcome Sanger Institute, the University of Oslo, Imperial College London and UCL have now mapped the evolution of this E. coli strain, its prevalence and distribution. Using high-resolution population genomics, whole genome sequencing (3) and advanced computational tools, they analysed 5,065 clinical samples from different countries and time periods. The data included large collections of samples from the UK and Norway, newly-generated adult and neonatal samples from six countries, such as Brazil, Mexico and Laos among others, and samples from the pre-antibiotic era - from 1932 onwards (4). 

They found that this specifically virulent capsule - K1 - actually dates further back in time, approximately 500 years earlier than previously imagined. This highlights the importance of the capsule for the bacterium’s survival and the role of the extracellular barrier in the success of E. coli  as the main cause of extraintestinal infections. 

Dr Sergio Arredondo-Alonso, lead author of the study from the University of Oslo and the Wellcome Sanger Institute, said: “It was exciting to discover the possibility of reconstructing the evolutionary history of the K1 capsule over the last half millennium, and to see how the capsule genes have been acquired over and over again by many different lineages of this pathogen species over the centuries. As neither the prevalence nor the history of K1 was known, it felt like we entered truly unchartered territory and significantly advanced understanding of this major pathogen species.”     

The study also shows that 25 per cent of all current E. coli strains responsible for blood infections contain the genetic information needed to develop the K1 capsule. Obtaining a complete evolutionary history of this strain will now allow researchers to understand how bacteria obtain the genetic material responsible for severe virulence in the first place, and analyse ways to combat them. 

By using enzymes from bacteriophages, which are viruses that ‘infect and kill’ bacteria, researchers were able to remove the bacterium’s extracellular barrier and make it vulnerable to the human immune system. The researchers demonstrated in in vitro studies using human serum - a liquid part of the blood that is commonly used in laboratory studies -  that targeting this capsule can be a way to broadly treat E. coli infection without the use of antibiotics, consistent with previous experimental infections in animals (5).  

Dr Alex McCarthy, a senior author of the study from Imperial College London, said: “We specifically demonstrated the advances made possible by combining experimental microbiology with population genomics and evolutionary modelling tools, to open a window into translating the findings into future clinical practice. We show that therapeutic targeting of the K1 capsule makes these pathogens more vulnerable to our immune system, and offers the possibility of preventing serious infections. For example, it could help treat newborn babies with meningitis caused by K1 E. coli, which is a rare but dangerous condition associated with high mortality and serious long-term adverse health effects.”

Professor Jukka Corander, a co-senior author of the study from the Wellcome Sanger Institute and the University of Oslo, said: “Our research shows the importance of representative genomic surveys of pathogens over time and space. These studies will enable us to reconstruct the evolutionary history of successful bacterial lineages and pinpoint changes in their genetic make-up that can lead to their ability to spread and cause disease. Such knowledge is ultimately providing the basis for designing future interventions and therapies against these pathogens.” 

ENDS

Contact details:

Alexandra Canet

Press Office

Wellcome Sanger Institute

Cambridge, CB10 1SA

Email: press.office@sanger.ac.uk

Notes to editors

1. Bacteria across a wide range of species produce capsular polysaccharides - an external barrier - that are associated with diverse functions. They have been shown to improve bacterial persistence and adaptation to new environments. 
2. E. coli infections: https://pubmed.ncbi.nlm.nih.gov/28201713/ 
3. Whole genome sequencing is a method that analyses the entire genome of an organism. 
4. Part of the Gladstone, Kallonen, Murray collection and the Horesh collection. 
5. In neonatal rats

Publication: Arredondo-Alonso, S., et al. (2023) Evolutionary and functional history of the Escherichia coli K1 capsule. Nature Communications. DOI: 10.1038/s41467-023-39052-w

Funding:

This work was financed by the Medical Research Council (MRC, UK); the Biotechnology and Biological Sciences Research Council (BBSRC, UK);  the European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions. This work has also received funding from the Trond Mohn Foundation. It was partially supported by the European Research Council (ERC) and the Joint Programming Initiative in Antimicrobial Resistance. A full acknowledgement list can be found in the publication. 

Selected websites:

University of Oslo

Founded in 1814, the Faculty of Medicine at the University of Oslo is the oldest medical faculty in Norway. The Faculty's core activities are research, education, dissemination and innovation for the best of patients and society.

Imperial College London

Imperial College London is a global top ten university with a world-class reputation. The College's 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business.    

The Research Excellence Framework (REF) 2021 [timeshighereducation.com] found that it has a greater proportion of world-leading research than any other UK university, it was named University of the Year 2022 [thetimes.co.uk] according to The Times and Sunday Times Good University Guide, University of the Year for Student Experience 2022 by the Good University Guide, and awarded a Queen’s Anniversary Prize [queensanniversaryprizes.org.uk] for its COVID-19 response. https://www.imperial.ac.uk/ [imperial.ac.uk]

The Wellcome Sanger Institute

The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.

About Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health. https://wellcome.org/